<DOC>
	<DOCNO>NCT01248052</DOCNO>
	<brief_summary>This two part study ( Parts A B ) , purpose determine safety LY2979165 healthy people , side effect might associate , understand body handle LY2979165 . In addition , Part B , also look level LY2979165 spinal fluid . Doses investigated range 20-1000 mg .</brief_summary>
	<brief_title>A First Human Dose Study Investigate Safety Tolerability LY2979165 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Are overtly healthy male female , determine medical history physical examination . Female subject Part B site 's discretion . Male subject : Agree use reliable method birth control study . Female subject : Women childbearing potential due surgical sterilisation ( hysterectomy bilateral oophorectomy tubal ligation ) postmenopausal define age great equal 45 year intact uterus , take hormone oral contraceptive &gt; 1 year , either : spontaneous amenorrhea &gt; 12 month , spontaneous amenorrhea 612 month follicle stimulate hormone ( FSH ) level &gt; 40 mIU/mL Are body mass index ( BMI ) 18.5 29.9 kg/m2 , inclusive . Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator . Have venous access sufficient allow blood sample per protocol . Are reliable willing make available duration study willing follow study procedure . Have give write informed consent approve Lilly ethical review board govern site . Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device , study drug/device use study , concurrently enrol type medical research judge scientifically medically compatible study . Are persons previously complete withdrawn study . History clinically significant adverse drug reaction `` drug allergy '' 3 different type systemically administer medication know allergy LY2979165 's constituent . Have Bazett 's correct QT ( QTcB ) interval value &gt; 450 msec ( male ) &gt; 470 msec ( female ) abnormality screen 12lead ECG , opinion investigator , increase risk associate participate study . Have abnormal blood pressure ( least 5 minute supine position ) determine investigator . Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , haematological , immunological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data . Have increase risk seizure evidence history : great equal 1 seizure ( except childhood febrile seizure ) , history electroencephalogram epileptiform activity , history stroke , surgery cerebral cortex , head trauma loss consciousness . Show evidence significant active neuropsychiatric disease . Have history alcohol drug abuse . Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody . Show evidence hepatitis B and/or positive hepatitis B surface antigen . Have donate blood 450 mL within last 3 month prior dose . Intended use overthecounter medication within 7 day prior dose study exception vitamins mineral supplement ( provide &gt; 100 % recommend dietary allowance [ RDA ] ) , occasional paracetamol acetaminophen . If situation arises , inclusion otherwise suitable subject may discretion sponsor . Intended use herbal supplement prescription medication , stable dos thyroid estrogen hormone replacement , within 14 day prior dose study . If situation arises , inclusion otherwise suitable subject may discretion sponsor . Subjects meet least 1 follow criterion ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) : subject average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , subject unwilling stop alcohol consumption 48 hour prior dose completion study appointment , subject unwilling limit alcohol intake 3 unit per day study appointment . Cigarette consumption 10 cigarette per day unable/unwilling abide CRU smoke restriction admission . Any condition , opinion investigator , would preclude participation study . In addition Part B : Abnormalities lumbar spine previously know determined screen lumbar xray . History clinically significant back pain , back pathology and/or back injury ( example , degenerative disease , spinal deformity spinal surgery ) may predispose complication technical difficulty lumbar puncture . Have evidence history significant active bleeding coagulation disorder take nonsteroidal anti inflammatory drug ( NSAIDs ) drug affect coagulation platelet function within 14 day prior lumbar catheter insertion . Have allergy lidocaine ( XylocaineÂ® ) derivative . Have medical surgical condition lumbar puncture contraindicate . Have participate Part A study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>